| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
94,014,000 |
| Market
Cap: |
1.97(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.39 - $24.57 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of cancer therapies. Co.'s two primary product candidates are, SNDX-5613 and SNDX-6352 or axatilimab. Co. is developing SNDX-5613, targeting the binding interaction of menin with the mixed lineage leukemia 1 (MLL1) protein for the treatment of MLL-rearranged acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia, as well as axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor. Co. has a collaboration and license agreement with Incyte Corporation for the development and commercialization of axatilimab.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
242,142 |
1,322,814 |
| Total Sell Value |
$0 |
$0 |
$4,873,574 |
$30,131,894 |
| Total People Sold |
0 |
0 |
3 |
8 |
| Total Sell Transactions |
0 |
0 |
5 |
37 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Egros Fabrice |
|
– • – |
2021-05-18 |
4 |
OE |
$7.20 |
$99,129 |
D/D |
13,609 |
29,609 |
|
- |
|
| Meyers Michael L. |
SVP, Chief Medical Officer |
• – – |
2021-04-26 |
4 |
B |
$15.46 |
$7,730 |
D/D |
500 |
15,666 |
0.01 |
14% |
|
| Podlesak Dennis |
|
– • – |
2021-04-22 |
4 |
B |
$14.11 |
$197,077 |
D/D |
13,967 |
43,300 |
0.01 |
23% |
|
| Egros Fabrice |
|
– • – |
2021-03-01 |
4 |
AS |
$24.31 |
$248,981 |
D/D |
(10,241) |
16,000 |
|
-31% |
|
| Egros Fabrice |
|
– • – |
2021-03-01 |
4 |
OE |
$6.35 |
$65,093 |
D/D |
10,241 |
26,241 |
|
- |
|
| Morrison Briggs |
Chief Executive Officer |
• • – |
2021-02-08 |
4 |
AS |
$20.55 |
$722,403 |
D/D |
(35,156) |
48,336 |
|
-9% |
|
| Morrison Briggs |
Chief Executive Officer |
• • – |
2021-02-08 |
4 |
OE |
$7.20 |
$253,123 |
D/D |
35,156 |
83,492 |
|
- |
|
| Egros Fabrice |
|
– • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,000 |
|
- |
|
| Meury William |
|
– • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,000 |
|
- |
|
| Podlesak Dennis |
|
– • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
29,333 |
29,333 |
|
- |
|
| Legault Pierre |
|
– • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,000 |
|
- |
|
| Jarrett Jennifer |
|
– • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,000 |
|
- |
|
| Katkin Keith |
|
– • – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
16,000 |
|
- |
|
| Metzger Michael A |
President and COO |
• • – |
2021-02-01 |
4 |
AS |
$20.19 |
$302,799 |
D/D |
(15,000) |
17,659 |
|
-11% |
|
| Metzger Michael A |
President and COO |
• • – |
2021-02-01 |
4 |
OE |
$7.20 |
$108,000 |
D/D |
15,000 |
32,659 |
|
- |
|
| Morrison Briggs |
Chief Executive Officer |
• • – |
2021-01-31 |
4 |
A |
$12.00 |
$21,252 |
D/D |
1,771 |
48,336 |
|
- |
|
| Meyers Michael L. |
SVP, Chief Medical Officer |
• – – |
2021-01-31 |
4 |
A |
$12.00 |
$21,252 |
D/D |
1,771 |
15,166 |
|
- |
|
| Metzger Michael A |
President and COO |
• • – |
2020-12-01 |
4 |
AS |
$22.97 |
$344,513 |
D/D |
(15,000) |
17,659 |
|
-9% |
|
| Metzger Michael A |
President and COO |
• • – |
2020-12-01 |
4 |
OE |
$7.20 |
$108,000 |
D/D |
15,000 |
32,659 |
|
- |
|
| Ordentlich Peter |
Chief Scientific Officer |
• – – |
2020-11-23 |
4 |
S |
$22.89 |
$694,121 |
D/D |
(29,972) |
0 |
|
-6% |
|
| Ordentlich Peter |
Chief Scientific Officer |
• – – |
2020-11-23 |
4 |
OE |
$3.08 |
$92,314 |
D/D |
29,972 |
29,972 |
|
- |
|
| Morrison Briggs |
Chief Executive Officer |
• • – |
2020-11-10 |
4 |
S |
$20.06 |
$350,312 |
D/D |
(17,466) |
46,565 |
|
-24% |
|
| Morrison Briggs |
Chief Executive Officer |
• • – |
2020-11-10 |
4 |
OE |
$7.20 |
$125,755 |
D/D |
17,466 |
64,031 |
|
- |
|
| Morrison Briggs |
Chief Executive Officer |
• • – |
2020-11-09 |
4 |
S |
$20.04 |
$1,261,265 |
D/D |
(62,938) |
46,565 |
|
-22% |
|
| Morrison Briggs |
Chief Executive Officer |
• • – |
2020-11-09 |
4 |
OE |
$7.20 |
$453,154 |
D/D |
62,938 |
109,503 |
|
- |
|
208 Records found
|
|
Page 7 of 9 |
|
|
0.78 (3.59%) 
